The Phase II trial examined the therapeutic cancer vaccine Tedopi in combination with chemotherapy drug combination FOLFIRI.

Kepler Capital analyst Nicolas Pauillac maintained a Buy rating on OSE Immunotherapeutics SA (6OP – Research Report) on March 12 and set a ...

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBDNANTES, France – March 6, 2025, 6:00pm CET - OSE ...

Anne-Laure Autret-Cornet has been the CFO of OSE Immunotherapeutics, a biotech dedicated to immuno-oncology and ...

Aviva Investors, the global asset management business of Aviva, has announced a £15 million investment with Oxford Science Enterprises.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Immunotherapeutics.